Defining the predictors of the placebo response in irritable bowel syndrome
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background and aims We sought to determine the components of irritable bowel syndrome (IBS) clinical trials that correlate with higher levels of placebo response. Methods We performed a systematic review of placebo-controlled trials in patients with IBS to assess which variables correlate with a higher placebo response. Placebo responses for global symptom improvement and for decreased abdominal pain were assessed. Univariate and multiple linear regression analyses were conducted. Results Higher rates of global improvement correlated with frequency of administration of study intervention ( r = .31, P = .03), duration of the study ( r = .28, P = .04), and overall treatment effect of the active agent being studied ( r = .33, P = .02). Higher rates of decreased abdominal pain correlated with the frequency of intervention ( r = .39, P = .02) and overall treatment effect ( r = .40, P = .01), whereas lower placebo response rates correlated with year of the study ( r = -.36, P = .03), median age ( r = -.38, P = .04), and duration of study run-in period ( r = -.33, P = .04). On multivariate analysis, global improvement in the placebo group was associated significantly with intervention frequency ( P = .0079), overall treatment response ( P = .0031), and parallel study design ( P = .0044). Decreased abdominal pain was associated significantly with frequency of intervention ( P = .0061) and overall treatment response ( P = .0128). Conclusions In IBS studies, higher placebo response rat…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A high ''placebo'' effect was observed in the control group in the present work, which confirms well-known data reported in IBS placebo-controlled trials showing an average placebo response rate of 40-45%.”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 102 · Cited by 111
Research works printed but not linked: 9
- Shetty, 1999, The placebo response in Parkinson’s disease, Clin Neuropharmacol, 22, 207
- Baldi, 1991, Clinical and functional evaluation of the efficacy of otilonium bromide, Ital J Gastroenterol, 23, 60
- Nayak, 1997, Metronidazole relieves symptoms in irritable bowel syndrome, Indian J Gastroenterol, 16, 137
- Baldi, 1992, Octylonium bromide in the treatment of the irritable bowel syndrome, Hepatogastroenterology, 39, 392
- Halpern, 1996, Treatment of irritable bowel syndrome with Lacteol Fort, Am J Gastroenterol, 91, 1579
- Misra, 1989, Long-term treatment of irritable bowel syndrome, QJM, 73, 931
- Tasman-Jones, 1973, Mebeverine in patients with the irritable colon syndrome, N Z Med J, 77, 232
- Yadav, 1989, Irritable bowel syndrome, Indian J Med Res, 90, 496
- Pimentel, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome, Am J Gastroenterol, 98, 412
Metadata
- Authors
- Pitz, M., Cheang, M., & Bernstein, C. N.
- Affiliations
- University of Manitoba (CA)
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 3
- Issue
- 3
- Pages
- 237-247
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2168787978
- Semantic Scholar
- a05939bbd85e964b955e608b59c385f029e2701d
- Cited by
- 111
- References
- 102
- Citations by year
- 2025: 3 · 2024: 2 · 2022: 3 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 11 · 2013: 4 · 2012: 4
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- irritable bowel syndrome, placebo response, predictors of placebo response, abdominal pain, intervention frequency, treatment effects, trial design, dosing frequency
- MeSH terms
- Clinical Trials as Topic, Drug Administration Schedule, Gastrointestinal Agents, Humans, Placebo Effect, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the predictors of the placebo response in irritable bowel syndrome. https://app.cochat.ai/papers/10.1016/s1542-3565(04)00626-3
- The paper
- Pitz, M., Cheang, M., & Bernstein, C. N. (2005). Defining the predictors of the placebo response in irritable bowel syndrome. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/s1542-3565(04)00626-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.